| Molecular formula | C212H350N56O78S |
|---|
| Molecular weight | 4963 g/mol |
|---|
| Registered trials | 18 |
|---|
| PubChem CID | 45382195 |
|---|
What thymosin beta-4 is
Thymosin beta-4 is a peptide compound (molecular formula C212H350N56O78S) that has not received approval from a regulatory agency for any medical use. No approved drug label exists for this compound, and it carries no approved brand name or indication. It is classified in chemical databases under a PubChem entry (CID 45382195) used for reference purposes.
Research and trial footprint
Thymosin beta-4 has been studied in a total of 18 registered clinical trials. Among the publicly listed studies, one phase 2 trial examined its use in patients with venous stasis ulcers and reached completed status. A phase 1b study in healthy volunteers also reached completed status, while a separate phase 2 study evaluating corneal wounds was terminated before completion. These trials reflect registered research activity and do not establish that the compound is safe or effective for any use.
FAQ
No. Thymosin beta-4 does not have an approved drug label from a regulatory agency. It remains an unapproved research compound studied in clinical trials rather than a marketed medication.
A total of 18 clinical trials have been registered for thymosin beta-4. These span different study designs and patient populations, including completed and terminated studies.
Registered trials have examined thymosin beta-4 in contexts such as venous stasis ulcers, corneal wounds, and general safety assessment in healthy volunteers. A trial result being registered does not confirm the compound works for these conditions.
Yes. A phase 2 study evaluating thymosin beta-4 for corneal wounds was listed with terminated status, meaning it did not run to its planned completion.
Thymosin beta-4 has the molecular formula C212H350N56O78S and is cataloged under PubChem CID 45382195 for reference. This identifier is used for chemical tracking rather than clinical classification.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem CID 45382195 ClinicalTrials.gov registry (18 trials) NCT00832091 NCT04555850 NCT00598871
Updated 2026-11-07